The therapy, which consists of cancer drugs Tafinlar and Mekinist, may now be used to treat inoperable or metastatic anaplastic thyroid cancer with a specific gene mutation.
“This is the first FDA-approved treatment for patients with this aggressive form of thyroid cancer, and the third cancer with this specific gene mutation that this drug combination has been approved to treat,” said Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research.
The combination therapy is also approved to treat a specific type of lung cancer and melanoma.
More articles on supply chain:
Commissioner Dr. Scott Gottlieb says FDA is ‘actively developing’ regulatory framework for AI technologies
South Dakota hospital keeps dumping medical waste in city landfill despite fines
McKesson adds Medtronic exec as independent director: 4 takeaways
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
